Produits et services

Software for the recording, viewing, or analyzing health and medical information; software applications for mobile devices for the recording, viewing, or analyzing health and medical information; web application software for the recording, viewing, or analyzing health and medical information. Scientific and technological services, namely, scientific research, analysis, testing, of medical devices and medicines in the field of pharmaceuticals and human healthcare; software as a service [SaaS]. Providing medical information, consultancy and advisory services relating to eye diseases, eye infections and eye symptoms; medical services relating to eye diseases, eye infections and eye symptoms; human healthcare services relating to eye diseases, eye infections and eye symptoms; medical and pharmaceutical counseling relating to eye diseases, eye infections and eye symptoms; treatment of eye diseases, eye infections and eye symptoms; offering medical information on diseases and on the treatment thereof.

Produits et services

Ophthalmologic preparations; eye drops; pharmaceutical preparations; veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use; food for babies; plasters; materials for dressings; material for stopping teeth; dental wax; disinfectants; fungicides; herbicides.

Produits et services

Eye drops for the reduction of myopia progression; collyrium; eye drops; ophthalmic pharmaceutical preparations; ophthalmological preparations; pharmaceutical preparations for the treatment of cataracts; pharmaceutical preparations for the treatment of glaucoma; pharmaceutical preparations for the treatment of ocular hypertension; ophthalmic ointments, creams, lotions and gels; pharmaceutical preparations for use in eye injections; pharmaceutical preparations for the treatment of pinguecula; pharmaceutical preparations for the treatment of chalazion; pharmaceutical preparations for the treatment of uveitis; pharmaceutical preparations for improving focus-adjustment function declined by accommodative asthenopia; pharmaceutical preparations for the treatment of accommodative asthenopia; eye drops for the treatment of keratoconjunctival epithelial disorder; antibacterial eye drops; antiallergic eye drops; pharmaceutical preparations; dietary supplements for humans; nutritional supplements.

Abrégé

A glaucoma drainage device is provided having an elongate body that drains aqueous humor from the anterior chamber of the eye. At least one anchor or wire is configured to extend radially outward beyond the body for fixing the body in the eye. The device including the anchor or wire can be housed within the distal end of a needle inserter and deployed therefrom to implant the device into the eye. The deployment can be carried out either ab externo or ab interno. When the device is loaded inside the needle inserter, the wire or anchor (or part thereof) is retained in a compressed state. When deployed from the needle inserter into the eye, the wire or anchor (or part thereof) is configured to automatically self-expand relative to the compressed state and fixate the device in the eye. Related systems and methods of treating glaucoma are also described and claimed.

Classes IPC  ?

• A61F 9/007 - Procédés ou dispositifs pour la chirurgie de l'œil
• A61M 27/00 - Appareillage pour drainage des blessures
• A61F 2/14 - Parties d'yeux, p. ex. cristallins ou implants de cornéeYeux artificiels
• A61B 17/34 - TrocartsAiguilles à ponction

Abrégé

Disclosed herein is an aqueous composition comprising 0.001-0.1% (w/v) atropine or a salt thereof, a water-soluble polymer, and buffer (1), which is at a pH range of 6 or lower, wherein the buffer (1) is at least one selected from the group consisting of a phosphate buffer, an aminocarboxylate buffer, a carbonate buffer, an acetate buffer, a tartrate buffer, a borate buffer, and trometamol.

Classes IPC  ?

• A61K 9/08 - Solutions
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/46 - Aza-8-bicyclo[3.2.1]octaneSes dérivés, p. ex. atropine, cocaïne
• A61K 47/02 - Composés inorganiques
• A61K 47/08 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant de l'oxygène
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/38 - CelluloseSes dérivés
• A61P 27/02 - Agents ophtalmiques
• A61P 27/08 - Mydriatiques ou cycloplégiques
• A61P 27/10 - Agents ophtalmiques pour le traitement des troubles d'accommodation, p. ex. myopie

Abrégé

A preventive or therapeutic agent for glaucoma or ocular hypertension includes a combination of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl) aminomethyl}pyridin-2-ylamino)acetate with one or more other preventive or therapeutic drugs for glaucoma or ocular hypertension, with the proviso that tafluprost is excluded.

Classes IPC  ?

• A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
• A61K 31/225 - Acides polycarboxyliques
• A61K 31/4178 - 1,3-Diazoles non condensés et contenant d'autres hétérocycles, p. ex. pilocarpine, nitrofurantoïne
• A61K 31/498 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinoxaline, phénazine
• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• A61K 31/542 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes hétérocycliques
• A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p. ex. clozapine, dilazèpe
• A61K 31/5575 - Eicosanoïdes, p. ex. leucotriènes ayant un cycle cyclopentane, p. ex. prostaglandine E2, prostaglandine F2-alpha
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles

Abrégé

The present invention provides an aqueous composition that improves transferability to eye tissue and a preservative effect, that comprises epinastine or a salt thereof in a concentration of 0.1% (w/v), boric acid and/or a salt thereof, and an isotonizing agent, and that has a pH of 6.0-7.7, wherein the concentration of the boric acid and/or the salt thereof is 150-500 mM in terms of boron concentration.

Classes IPC  ?

• A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
• A61K 9/08 - Solutions
• A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
• A61P 27/14 - Décongestionnants ou antiallergiques

Produits et services

Intraocular prostheses [lenses] for surgical implantation; intraocular lens injector; eye droppers for medical purposes; glaucoma tube shunt; surgical apparatus and instruments for use in ophthalmic surgery; medical devices for non-laser glaucoma surgery; ocular implants and devices; shunts for use in treating glaucoma; stents for use in treating glaucoma; ophthalmic cutting instruments for use in treating glaucoma; shunt and stent applicators for use in treating glaucoma; vision screening instruments for use in treating glaucoma; ocular implants and devices for use in treating glaucoma; ophthalmic medical devices; syringes for medical purposes; medical apparatus; eye wash cups for medical purposes; finger guards for medical purposes; pacifier clips; ice bag pillows for medical purposes; triangular bandages; supportive bandages; surgical catguts; feeding cups for medical purposes; dropping pipettes for medical purposes; medical ice bags; medical ice bag holders; nursing bottles; contraceptive devices; artificial tympanic membranes; prosthetic or filling materials, not for dental use; esthetic massage apparatus for commercial use; electric massage apparatus for household use; gloves for medical purposes.

Abrégé

The present disclosure provides a pharmaceutical composition comprising ursodeoxycholic acid or a salt thereof, a preservative, and water.

Classes IPC  ?

• A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61P 27/10 - Agents ophtalmiques pour le traitement des troubles d'accommodation, p. ex. myopie

Abrégé

The present invention provides a pharmaceutical composition for application to the skin comprising epinastine or a salt thereof in a concentration of 0.05 to 1% (w/w) as an active ingredient which can maintain the concentration of the active ingredient for a long time even at lower concentrations.

Classes IPC  ?

• A61K 9/107 - Émulsions
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
• A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
• A61P 27/14 - Décongestionnants ou antiallergiques

Abrégé

The present invention provides a pharmaceutical composition for transdermal administration comprising epinastine or a salt thereof as an active ingredient which can maintain the effective concentration of epinastine or a salt thereof in an ocular tissue and stabilize epinastine or a salt thereof in the pharmaceutical composition for a long time.

Classes IPC  ?

• A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/107 - Émulsions
• A61K 47/06 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
• A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
• A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
• A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline

Produits et services

Ophthalmic preparations.

Abrégé

The present disclosure provides a pharmaceutical composition containing ursodeoxycholic acid or a salt thereof, trometamol or a salt thereof, and water, the pharmaceutical composition having an osmotic pressure of 50-400 mOsm/L, and the amount of trometamol or a salt thereof contained in the pharmaceutical composition being 0.01-3%(w/v).

Classes IPC  ?

• A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
• A61K 9/08 - Solutions
• A61K 47/02 - Composés inorganiques
• A61K 47/04 - Non-métauxLeurs composés
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61P 27/02 - Agents ophtalmiques
• A61P 27/10 - Agents ophtalmiques pour le traitement des troubles d'accommodation, p. ex. myopie

Abrégé

The purpose of the present invention is to provide a pharmaceutical composition that comprises a specific compound and exhibits a superior preservation efficacy, the specific compound being stable within the pharmaceutical composition, and to provide methods for improving the stability of the specific compound within the pharmaceutical composition and the preservation efficacy of the pharmaceutical composition. The pharmaceutical composition according to the present invention comprises isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof, and further comprises edetic acid or a salt thereof.

Classes IPC  ?

• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline

Abrégé

Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.

Classes IPC  ?

• A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
• A61P 27/06 - Agents antiglaucomateux ou myotiques
• A61P 27/02 - Agents ophtalmiques
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

The present invention provides a stable pharmaceutical composition comprising (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof and a method of stabilizing (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof.

Classes IPC  ?

• A61K 31/5513 - 1,4-Benzodiazépines, p. ex. diazépam
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides

Abrégé

The purpose of the present invention is to provide: a pharmaceutical composition that comprises the pyridylaminoacetic acid compound of the present invention, said pyridylaminoacetic acid compound being stable within the pharmaceutical composition; and a method for improving the stability of the pydridylaminoacetic acid compound within the pharmaceutical composition. The pharmaceutical composition comprises: (6{[4-(pyrazol-1-yl)benzyl](pyridine-3-ylsulfonyl)aminomethyl}pyridine-2-ylamino)isopropyl acetate or a salt thereof; and polyoxyethylene castor oil. The polyoxyethylene castor oil preferably comprises a polyoxyethylene castor oil selected from the group consisting of polyoxyl 5 castor oil, polyoxyl 9 castor oil, polyoxyl 15 castor oil, polyoxyl 35 castor oil, and polyoxyl 40 castor oil.

Classes IPC  ?

• A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
• A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
• A61K 47/02 - Composés inorganiques
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

A method of delivering a dose from a single dose syringe includes applying a user input to a rotational component of a plunger rod assembly that is engaged with a plunger rod of the plunger rod assembly to advance a plunger seal in a direction parallel to an axis of rotation of the rotational component from an initial position towards a start of dose delivery position, and upon disengagement of the rotational component from the plunger rod, applying an axial user input to the plunger rod of the plunger rod assembly to advance the plunger seal from the start of dose delivery position to a completion of dose delivery position to deliver the dose, wherein the completion of dose delivery position is defined by abutment between the plunger rod and a housing of the plunger rod assembly.

Classes IPC  ?

• A61M 5/315 - PistonsTiges de pistonGuidage, blocage, ou limitation des mouvements de la tigeAccessoires disposés sur la tige pour faciliter le dosage
• A61F 9/00 - Procédés ou dispositifs pour le traitement des yeuxDispositifs pour mettre en place des verres de contactDispositifs pour corriger le strabismeAppareils pour guider les aveuglesDispositifs protecteurs pour les yeux, portés sur le corps ou dans la main
• A61M 5/31 - Seringues Parties constitutives
• A61M 5/34 - Structures pour le raccordement de l'aiguille
• A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
• A61M 39/10 - Raccords ou accouplements pour tubes

Abrégé

The present disclosure provides an agent for treating or preventing an eye disease such as presbyopia, comprising, as an active ingredient, a sulfur-containing compound having a specified structure.

Classes IPC  ?

• A61K 31/385 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant plusieurs atomes de soufre dans le même cycle
• A61K 31/095 - Composés du soufre, du sélénium ou du tellure, p. ex. thiols
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 27/10 - Agents ophtalmiques pour le traitement des troubles d'accommodation, p. ex. myopie

Abrégé

The purpose of the present invention is to discover a method for stabilizing a composition for ophthalmic use containing sepetaprost, more specifically, a method that facilitates retention of sepetaprost stability at high temperatures, and further, a method that facilitates the retention of shelf life of this composition for ophthalmic use.　The present invention is a composition for ophthalmic use, which contains sepetaprost at a concentration of 0.0001 to 0.003% (w/v) and has a pH within a range from 5 to 8.

Classes IPC  ?

• A61K 31/558 - Eicosanoïdes, p. ex. leucotriènes ayant des hétérocycles contenant l'oxygène comme seul hétéro-atome du cycle, p. ex. thromboxanes
• A61K 9/08 - Solutions
• A61K 47/02 - Composés inorganiques
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61P 27/02 - Agents ophtalmiques
• A61P 27/06 - Agents antiglaucomateux ou myotiques

Abrégé

The present invention provides a pharmaceutical preparation in which an aqueous pharmaceutical composition, which contains (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof, is housed in a packaging that blocks light rays of 210-380 nm in wavelength. In this pharmaceutical preparation, the stability of (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof in the aqueous pharmaceutical composition has been improved.

Classes IPC  ?

• A61K 31/5513 - 1,4-Benzodiazépines, p. ex. diazépam
• A61K 9/08 - Solutions
• A61P 27/06 - Agents antiglaucomateux ou myotiques

Abrégé

The present invention provides an effective production method and/or purification method for a high-yield and high-purity (R)-11-[[-[(diethylamino)methyl]-1-piperidinyl]-acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine-6-one or a salt thereof, said compound not containing impurities, particularly 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine-6-one.

Classes IPC  ?

• C07D 471/04 - Systèmes condensés en ortho
• A61K 31/5513 - 1,4-Benzodiazépines, p. ex. diazépam
• A61P 27/02 - Agents ophtalmiques
• A61P 27/06 - Agents antiglaucomateux ou myotiques

Abrégé

The invention relates to an object comprising a polymer composition comprising a biodegradable polymer and mitomycin C, wherein i) the object is a mesh of fibers comprising the polymer composition or ii) the object is a multilayer film comprising a first outer layer and a second outer layer and an inner layer provided between and adhered to the first outer layer and the second outer layer, wherein the inner layer comprises the polymer composition and each of the first outer layer and a second outer layer comprises a biodegradable polymer.

Classes IPC  ?

• A61K 9/70 - Bases pour bande, feuille ou filament
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

The purpose of the present invention is to identify a drug formulation for the treatment or prevention of glaucoma or ocular hypertension, wherein the drug formulation exhibits an effect in patients with drug-refractory glaucoma or ocular hypertension. Sepetaprost is expected to exhibit an excellent intraocular pressure-lowering action in patients with otherwise drug-refractory glaucoma or ocular hypertension. The drug formulation according to the present invention containing sepetaprost as an active ingredient is therefore useful as a drug formulation that can treat or prevent glaucoma or ocular hypertension in patients with otherwise drug-refractory glaucoma or ocular hypertension.

Classes IPC  ?

• A61K 31/558 - Eicosanoïdes, p. ex. leucotriènes ayant des hétérocycles contenant l'oxygène comme seul hétéro-atome du cycle, p. ex. thromboxanes
• A61P 27/06 - Agents antiglaucomateux ou myotiques
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

The present invention provides an improvement in the strength of the scleral by collagen fiber crosslinking via crosslinking treatment of the sclera at the equatorial region of the eye and/or at the posterior pole such as the fundus of the eye. Also provided is the prevention and/or treatment of eye disease by the same. Provided are a photosensitizer used in a crosslinking treatment for the sclera at the equatorial region of the eye and/or at the posterior pole of the eye; a kit containing the same; and a method for emitting light for the crosslinking treatment.

Classes IPC  ?

• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/525 - Iso-alloxazines, p. ex. riboflavines, vitamine B2
• A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
• A61K 31/7084 - Composés ayant deux nucléosides ou nucléotides, p. ex. dinucléotide de la nicotinamide-adénine, dinucléotide de la flavine-adénine

Abrégé

The present invention aims to find a pharmaceutical preparation which treats or prevents glaucoma or ocular hypertension and is effective for patients with inadequate efficacies of glaucoma or ocular hypertension therapeutic agents. It has been found that omidenepag, an ester thereof, or a salt thereof has an excellent intraocular pressure lowering efficacy on patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents. Therefore, the omidenepag, the ester thereof, or the salt thereof of the present invention is useful as a pharmaceutical preparation which can treat or prevent glaucoma or ocular hypertension even in patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents.

Classes IPC  ?

• A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/5575 - Eicosanoïdes, p. ex. leucotriènes ayant un cycle cyclopentane, p. ex. prostaglandine E2, prostaglandine F2-alpha

Produits et services

Software for the recording, viewing, or analyzing health and medical information; software applications for mobile devices for the recording, viewing, or analyzing health and medical information. Scientific and technological services, namely, scientific research, analysis, testing, of medical devices and medicines in the field of pharmaceuticals and human healthcare; offering information on diseases and on the treatment thereof. Providing medical information, consultancy and advisory services relating to eye diseases, eye infections and eye symptoms; Medical services relating to eye diseases, eye infections and eye symptoms; human healthcare services relating to eye diseases, eye infections and eye symptoms; medical and pharmaceutical counseling relating to eye diseases, eye infections and eye symptoms.

Abrégé

A method for suppressing obstruction of meibomian gland in a mammalian subject, the method comprising administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to an eye of the mammalian subject 1 to 2 times per day.

Classes IPC  ?

• A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal

Abrégé

The present invention relates to a pharmaceutical composition for treating myopia, preventing myopia and/or suppressing myopia progression, comprising (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof as an active ingredient, wherein the pharmaceutical composition is substantially free of (−)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof.

Classes IPC  ?

• A61K 31/5513 - 1,4-Benzodiazépines, p. ex. diazépam
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 27/06 - Agents antiglaucomateux ou myotiques

Abrégé

Implantable devices and systems and methods are provided for controlled delivery of a therapeutic agent to the eye, which employ a flexible reservoir for holding a supply of the therapeutic agent, and a flexible tube that extends from the reservoir. The tube has an inlet end in fluid communication with the interior space of the reservoir, an outlet end spaced from the reservoir, and a lumen that extends from the inlet end to the outlet end. The lumen of the tube is configured to deliver therapeutic agent from the reservoir through the tube.

Classes IPC  ?

• A61F 9/00 - Procédés ou dispositifs pour le traitement des yeuxDispositifs pour mettre en place des verres de contactDispositifs pour corriger le strabismeAppareils pour guider les aveuglesDispositifs protecteurs pour les yeux, portés sur le corps ou dans la main

Produits et services

Collyrium; eye drops; ophthalmic pharmaceutical preparations; ophthalmological preparations; pharmaceutical preparations for treatment of cataracts; pharmaceutical preparations for treatment of glaucoma; pharmaceutical preparations for treatment of ocular hypertension; ophthalmic ointments, creams, lotions and gels; pharmaceutical preparations for use in eye injections; pharmaceutical preparations for treatment of pinguecula; pharmaceutical preparations for treatment of chalazion; pharmaceutical preparations for treatment of uveitis; pharmaceutical preparations for improving focus-adjustment function declined by accommodative asthenopia; pharmaceutical preparations for treatment of accommodative asthenopia; eye drops for treatment of keratoconjunctival epithelial disorder; antibacterial eye drops; antiallergic eye drops; pharmaceutical preparations; reagent paper for medical purposes; oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for medical use; capsules for medicines; eyepatches for medical purposes; ear bandages for medical purposes; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; cotton sticks for medical purposes; diapers; diaper covers; dietary supplements for humans; nutritional supplements; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; dietary supplements for animals.

Produits et services

Collyrium; eye drops; ophthalmic pharmaceutical preparations; ophthalmological preparations; pharmaceutical preparations for treatment of cataracts; pharmaceutical preparations for treatment of glaucoma; pharmaceutical preparations for treatment of ocular hypertension; ophthalmic ointments, creams, lotions and gels; pharmaceutical preparations for use in eye injections; pharmaceutical preparations for treatment of pinguecula; pharmaceutical preparations for treatment of chalazion; pharmaceutical preparations for treatment of uveitis; pharmaceutical preparations for improving focus-adjustment function declined by accommodative asthenopia; pharmaceutical preparations for treatment of accommodative asthenopia; eye drops for treatment of keratoconjunctival epithelial disorder; antibacterial eye drops; antiallergic eye drops; pharmaceutical preparations; reagent paper for medical purposes; oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for medical use; capsules for medicines; eyepatches for medical purposes; ear bandages for medical purposes; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; cotton sticks for medical purposes; diapers; diaper covers; dietary supplements for humans; nutritional supplements; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; dietary supplements for animals.

Abrégé

The present invention relates to an ophthalmic aqueous composition containing a silver salt, and filled in a container made of a polyester-based resin, or a container made of a polyolefin-based resin excluding polypropylene. Besides, the present invention also relates to an ophthalmic preservative containing a silver salt, and filled in a container made of a polyester-based resin or a container made of a polyolefin-based resin excluding polypropylene, and a method for imparting, to an ophthalmic aqueous composition, preservative efficacy satisfying a criterion of Preservatives-Effectiveness Tests of The Japanese Pharmacopoeia, including adding a silver salt to the ophthalmic aqueous composition, and filling the ophthalmic aqueous composition in a container made of a polyester-based resin or a container made of a polyolefin-based resin excluding polypropylene. The present invention provides a preservative/system widely usable in ophthalmic aqueous compositions regardless of types of active ingredients and additives.

Classes IPC  ?

• A61K 47/02 - Composés inorganiques
• A61J 1/14 - Récipients spécialement adaptés à des fins médicales ou pharmaceutiques DétailsAccessoires à cet effet
• A61K 9/08 - Solutions
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/4704 - 2-Quinolones, p. ex. carbostyrile
• A61K 31/7084 - Composés ayant deux nucléosides ou nucléotides, p. ex. dinucléotide de la nicotinamide-adénine, dinucléotide de la flavine-adénine
• A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine

Abrégé

The present disclosure provides: a sulfur-containing compound which has a predetermined structure and is useful for treating or preventing eye diseases such as presbyopia and cataracts; and an agent for treating or preventing eye diseases such as presbyopia and cataracts, the agent containing said sulfur-containing compound as an active ingredient.

Classes IPC  ?

• A61K 31/4025 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil non condensés et contenant d'autres hétérocycles, p. ex. cromakalim
• A61K 31/4155 - 1,2-Diazoles non condensés et contenant d'autres hétérocycles
• A61K 31/4178 - 1,3-Diazoles non condensés et contenant d'autres hétérocycles, p. ex. pilocarpine, nitrofurantoïne
• A61K 31/4192 - 1,2,3-Triazoles
• A61K 31/422 - Oxazoles non condensés et contenant d'autres hétérocycles
• A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
• A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
• A61P 27/02 - Agents ophtalmiques
• C07D 409/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 413/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques

Abrégé

A compound useful for preventing or treating dry eye and a medicament for preventing and/or treating dry eye comprising the same which does not substantially impact on the intraocular pressure are provided. The present invention relates to a medicament for preventing and/or treating dry eye, comprising olodaterol or a salt thereof as an active ingredient.

Classes IPC  ?

• A61K 31/538 - 1,4-Oxazines, p. ex. morpholine condensées en ortho ou en péri avec des systèmes carbocycliques
• A61P 27/02 - Agents ophtalmiques
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

A compound useful for preventing or treating dry eye and a medicament for preventing and/or treating dry eye comprising the same which does not substantially impact on the intraocular pressure are provided. The present invention relates to a medicament for preventing and/or treating dry eye, comprising olodaterol or a salt thereof as an active ingredient.

Classes IPC  ?

• A61K 31/538 - 1,4-Oxazines, p. ex. morpholine condensées en ortho ou en péri avec des systèmes carbocycliques
• A61P 27/02 - Agents ophtalmiques
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

The purpose of the present invention is to provide an aqueous suspension composition comprising poorly water-soluble sirolimus or a salt thereof for ophthalmology, in particular, used for topical administration, such as a less invasive eye drop. The purpose of the present invention is to provide an aqueous suspension composition comprising poorly water-soluble sirolimus or a salt thereof for ophthalmology, in particular, used for topical administration, such as a less invasive eye drop. The present invention is an ophthalmic aqueous suspension composition comprising sirolimus or a salt thereof and a surfactant, wherein the aqueous suspension composition has a pH of 4 to 6.

Classes IPC  ?

• A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 9/10 - DispersionsÉmulsions
• A61K 47/38 - CelluloseSes dérivés
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés

Abrégé

A glaucoma drainage device includes an elongated body extending axially from a distal end to a proximal end. The distal end forms a wedge with a leading distal edge. During implantation of the device into the suprachoroidal space of the eye, the wedge can facilitate penetration into and spreading open the tissue of the suprachoroidal space. The elongate body has one or more outer surfaces that define at least one open groove extending from at or near the proximal end towards the distal end of the body. With the distal end of the elongate body located in the suprachoroidal space of the eye and the distal end of the elongate body extending into the anterior chamber of the eye, the at least one open groove is configured such that aqueous humor flows along the open groove from the anterior chamber of the eye to the suprachoroidal space of the eye.

Classes IPC  ?

• A61F 9/007 - Procédés ou dispositifs pour la chirurgie de l'œil

Abrégé

The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.

Classes IPC  ?

• A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
• A61P 27/10 - Agents ophtalmiques pour le traitement des troubles d'accommodation, p. ex. myopie
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

The present invention relates to the use of valproic acid for reducing post-operative scarring following a glaucoma surgery. In one embodiment, the glaucoma surgery is glaucoma filtering surgery, which comprises creating a subconjunctival bleb. In another embodiment, the glaucoma surgery is minimally invasive glaucoma surgery (MIGS), which comprises implanting a glaucoma tube shunt under a subconjunctival space.

Classes IPC  ?

• A61K 31/20 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique
• A61P 27/02 - Agents ophtalmiques
• A61P 41/00 - Médicaments utilisés en chirurgie, p. ex. adjuvants chirurgicaux pour la prévention des adhérences ou pour le remplacement de l'humeur vitrée

Produits et services

Educational services..

Abrégé

Described is a combination of a prophylactic or therapeutic agent for glaucoma or ocular hypertension, which is useful as a prophylactic or therapeutic agent for glaucoma or ocular hypertension. By combining sepetaprost and a Rho-associated coiled-coil containing protein kinase inhibitor(s), an intraocular pressure lowering action is enhanced as compared with the case where each drug is used alone. As the form of administration, they may be administered concomitantly or may be administered as a combination drug.

Classes IPC  ?

• A61K 31/335 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine
• A61K 31/472 - Isoquinoléines non condensées, p. ex. papavérine
• A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p. ex. clozapine, dilazèpe
• A61P 27/06 - Agents antiglaucomateux ou myotiques

Abrégé

An examination system (1000) comprises: a camera (16); a processor (21) for examining the wetness of an eye, on the basis of captured images obtained as a result of the camera (16) imaging the eye, and an estimation model (232) that includes a neural network (2321); and a display (15) that displays the results of the examination executed by the processor (21).

Classes IPC  ?

• G06T 7/00 - Analyse d'image
• A61B 3/10 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient

Produits et services

Educational services. Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; hosting of websites. Medical services; providing medical information; medical counselling services; provision of pharmaceutical information.

Abrégé

Disclosed herein are medical devices, such as intraocular shunts, that are made from materials comprising non-degradable, swellable polymer hydrogels, and methods of making and using the same.

Classes IPC  ?

• A61F 9/007 - Procédés ou dispositifs pour la chirurgie de l'œil
• A61L 31/04 - Matériaux macromoléculaires

Abrégé

The present disclosure provides a pharmaceutical composition comprising ursodeoxycholic acid or a salt thereof, a preservative agent and water.

Classes IPC  ?

• A61K 9/08 - Solutions
• A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
• A61K 47/04 - Non-métauxLeurs composés
• A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61P 27/02 - Agents ophtalmiques
• A61P 27/04 - Larmes artificiellesSolutions d'irrigation

Abrégé

The present disclosure provides a pharmaceutical composition comprising ursodeoxycholic acid or a salt thereof, a preservative agent and water.

Classes IPC  ?

• A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
• A61K 9/08 - Solutions
• A61K 47/04 - Non-métauxLeurs composés
• A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61P 27/02 - Agents ophtalmiques
• A61P 27/04 - Larmes artificiellesSolutions d'irrigation

Produits et services

Educational services. Scientific and technological services; offering scientific information on diseases and on the treatment thereof; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; hosting of websites. Medical services; healthcare services; providing of medical information; medical counselling services; provision of pharmaceutical information.

Produits et services

(1) Educational services in the field of eye care and eye treatment products (2) Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; hosting websites. (3) Medical services, namely, medical analysis for ophthalmological and eye disease prevention, screening, diagnosis and treatment; Providing medical information in the field of eye care and eye treatment; Medical counselling in the field of eye care and eye treatment; provision of pharmaceutical information.

Abrégé

The present invention provides a method for producing a layered retinal tissue including photoreceptor cells from pluripotent stem cells or an aggregate including retinal progenitor cells within a short period.

Classes IPC  ?

• C12N 5/079 - Cellules neurales
• C12Q 1/06 - Détermination quantitative

Abrégé

The present invention provides a pharmaceutical composition for topical administration, which contains epinastine or a salt thereof as an active ingredient at a concentration of 0.05 to 1% (w/w) and which enables long-term retention of the active ingredient concentration in eye tissue even when the dose is a low concentration.

Classes IPC  ?

• A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p. ex. clozapine, dilazèpe
• A61K 9/06 - OnguentsExcipients pour ceux-ci
• A61K 9/107 - Émulsions
• A61K 47/06 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
• A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
• A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
• A61P 27/02 - Agents ophtalmiques
• A61P 27/14 - Décongestionnants ou antiallergiques
• A61P 37/08 - Agents antiallergiques

Abrégé

The present invention provides a pharmaceutical composition for transdermal administration, the pharmaceutical composition being capable of maintaining an effective concentration in eye tissue and maintaining stability for a long time, and containing epinastine or a salt thereof and a sulfur-based antioxidant.

Classes IPC  ?

• A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
• A61K 9/06 - OnguentsExcipients pour ceux-ci
• A61K 9/10 - DispersionsÉmulsions
• A61K 9/107 - Émulsions
• A61K 47/02 - Composés inorganiques
• A61K 47/06 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
• A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
• A61P 27/02 - Agents ophtalmiques
• A61P 27/14 - Décongestionnants ou antiallergiques
• A61P 39/06 - Antiradicaux libres ou antioxydants

Produits et services

Collyrium; eye drops; ophthalmic pharmaceutical preparations; ophthalmological preparations; pharmaceutical preparations for treatment of cataracts; pharmaceutical preparations for treatment of glaucoma; pharmaceutical preparations for treatment of ocular hypertension; ophthalmic ointments, creams, lotions and gels; pharmaceutical preparations for use in eye injections; pharmaceutical preparations for treatment of pinguecula; pharmaceutical preparations for treatment of chalazion; pharmaceutical preparations for treatment of uveitis; pharmaceutical preparations for improving focus-adjustment function declined by accommodative asthenopia; pharmaceutical preparations for treatment of accommodative asthenopia; eye drops for treatment of keratoconjunctival epithelial disorder; antibacterial eye drops; antiallergic eye drops; pharmaceutical preparations; reagent paper for medical purposes; oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for medical use; capsules for medicines; eyepatches for medical purposes; ear bandages for medical purposes; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; cotton sticks for medical purposes; diapers; diaper covers; dietary supplements for humans; nutritional supplements; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; dietary supplements for animals.

Produits et services

(1) Pharmaceutical preparations for ophthalmological use; Sanitary preparations for medical purposes for the treatment of eye diseases and eye conditions.

Produits et services

Collyrium; eye drops; ophthalmic pharmaceutical preparations; ophthalmological preparations; pharmaceutical preparations for treatment of cataracts; pharmaceutical preparations for treatment of glaucoma; pharmaceutical preparations for treatment of ocular hypertension; ophthalmic ointments, creams, lotions and gels; pharmaceutical preparations for use in eye injections; pharmaceutical preparations for treatment of pinguecula; pharmaceutical preparations for treatment of chalazion; pharmaceutical preparations for treatment of uveitis; pharmaceutical preparations for improving focus-adjustment function declined by accommodative asthenopia; pharmaceutical preparations for treatment of accommodative asthenopia; eye drops for treatment of keratoconjunctival epithelial disorder; antibacterial eye drops; antiallergic eye drops; pharmaceutical preparations; reagent paper for medical purposes; oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for medical use; capsules for medicines; eyepatches for medical purposes; ear bandages for medical purposes; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; cotton sticks for medical purposes; diapers; diaper covers; dietary supplements for humans; nutritional supplements; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; dietary supplements for animals.

Produits et services

Breath freshening preparations; soaps and detergents; dentifrices; cosmetics; make-up powder; toilet water; beauty serums; eye cream for cosmetic purposes; beauty balm creams; gel eye patches for cosmetic purposes; gel eye masks; cosmetic creams; cosmetic oils; eye lotions for cosmetic purposes; cosmetic rouges; hair care preparations; perfumes; natural perfumery prepared from vegetables; natural perfumery prepared from animals; synthetic perfumery; blended perfumery; incense; false eyelashes. Collyrium; eye drops; medicinal creams; medicated lotions; balms for medical purposes; ointments for pharmaceutical purposes; ophthalmic preparations; pharmaceutical preparations; reagent paper for medical purposes; oiled paper for medical purposes; tapes (adhesive -), for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for dressings; empty capsules for pharmaceuticals; eyepatches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary pads; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; cotton swabs for medical use; dental materials; diapers; diaper covers; fly catching paper; mothproofing paper; lacteal flour for babies; dietary supplements for humans; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; dietary supplements for animals; semen for artificial insemination. Intraocular lenses; intraocular lens injector; eye droppers for medical purposes; glaucoma tube shunt; ophthalmologic apparatus and instruments; syringes for medical purposes; medical apparatus and instruments; cups for eye-washes; finger guards for medical purposes; pacifier clips; ice bag pillows for medical purposes; triangular bandages; supportive bandages; surgical catguts; feeding cups for medical purposes; dropping pipettes for medical purposes; teats; ice bags for medical purposes; medical ice bag holders; baby bottles; nursing bottles; contraceptive devices; artificial tympanic membranes; prosthetics or fillings materials, not for dental use; ear plugs for sleeping; ear plugs for protection against noise; esthetic massage apparatus for commercial use; electric massage apparatus for household purposes; gloves for medical purposes; portable hand-held urinals; bed pans; ear picks; sanitary masks for medical purposes; parts, fittings and accessories for all the aforementioned goods. Advertising and publicity services; promoting the goods and services of others through the administration of sales and promotional incentive schemes involving trading stamps; business management analysis or business consultancy; marketing research or analysis; providing information concerning commercial sales; business management; business administration services for the processing of sales made on the internet; promoting the goods and services of others over the internet; provision of an online marketplace for buyers and sellers of goods and services; commercial intermediation services; commercial administration of the licensing of the goods and services of others; administration of consumer loyalty programs; website traffic optimization; presentation of goods on communication media, for retail purposes; auctioneering; import-export agency services; publicity material rental; rental of advertising space; providing commercial information and advice for consumers in the choice of products and services; retail services or wholesale services for pharmaceutical, veterinary and sanitary preparations and medical supplies; retail services or wholesale services for cosmetics, toiletries, dentifrices, soaps and detergents. Educational and instruction services relating to arts, crafts, sports or general knowledge; teaching; educational and instruction services; teaching in the field of cosmetics and medicines; arranging, conducting and organization of seminars; arranging and conducting of seminars, workshops [education], congresses, colloquia, distance learning courses and exhibitions for cultural purposes; providing electronic publications; providing videos from the internet, not downloadable; providing digital music from the internet, not downloadable; providing images from the internet, not downloadable; entertainment services; entertainment information; photography. Providing information about beauty; beauty consultancy; provision of medical information; providing information relating to ophthalmology services; dietary and nutritional guidance; providing information relating to dietary and nutritional guidance; providing information relating to nursing care; nursing home services; medical equipment rental; providing information relating to the rental of medical machines and apparatus; health care.

Produits et services

Breath freshening preparations; soaps and detergents; dentifrices; cosmetics; make-up powder; toilet water; beauty serums; eye cream for cosmetic purposes; beauty balm creams; gel eye patches for cosmetic purposes; gel eye masks; cosmetic creams; cosmetic oils; eye lotions for cosmetic purposes; cosmetic rouges; hair care preparations; perfumes; materials; natural perfumery prepared from vegetables; natural perfumery prepared from animals; synthetic perfumery; blended perfumery; incense; false eyelashes. Collyrium; eye drops; medicinal creams; medicated lotions; balms for medical purposes; ointments for pharmaceutical purposes; ophthalmic preparations; pharmaceutical preparations; reagent paper for medical purposes; oiled paper for medical purposes; tapes (adhesive -), for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for dressings; empty capsules for pharmaceuticals; eyepatches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary pads; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; cotton swabs for medical use; dental materials; diapers; diaper covers; fly catching paper; mothproofing paper; lacteal flour for babies; dietary supplements for humans; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; dietary supplements for animals; semen for artificial insemination. Laboratory apparatus and instruments; measuring or testing machines and instruments; sensors [measurement apparatus], other than for medical use; telecommunication machines and apparatus; personal digital assistants; application software for mobile devices; electronic machines, apparatus and their parts; computer programs; computers and their peripherals; computer software applications, downloadable; computer software, recorded; eyeglasses; downloadable music files; downloadable image files; downloadable video files; electronic publications; parts, fittings and accessories for all the aforementioned goods. Intraocular lenses; intraocular lens injector; eye droppers for medical purposes; glaucoma tube shunt; ophthalmologic apparatus and instruments; syringes for medical purposes; medical apparatus and instruments; cups for eye-washes; finger guards for medical purposes; pacifier clips; ice bag pillows for medical purposes; triangular bandages; supportive bandages; surgical catguts; feeding cups for medical purposes; dropping pipettes for medical purposes; teats; ice bags for medical purposes; medical ice bag holders; baby bottles; nursing bottles; contraceptive devices; artificial tympanic membranes; prosthetics or fillings materials, not for dental use; ear plugs for sleeping; ear plugs for protection against noise; esthetic massage apparatus for commercial use; electric massage apparatus for household purposes; gloves for medical purposes; portable hand-held urinals; bed pans; ear picks; sanitary masks for medical purposes; parts, fittings and accessories for all the aforementioned goods. Advertising and publicity services; promoting the goods and services of others through the administration of sales and promotional incentive schemes involving trading stamps; business management analysis or business consultancy; marketing research or analysis; providing information concerning commercial sales; business management; business administration services for the processing of sales made on the internet; promoting the goods and services of others over the internet; provision of an online marketplace for buyers and sellers of goods and services; commercial intermediation services; commercial administration of the licensing of the goods and services of others; administration of consumer loyalty programs; website traffic optimization; presentation of goods on communication media, for retail purposes; auctioneering; import-export agency services; publicity material rental; rental of advertising space; providing commercial information and advice for consumers in the choice of products and services; retail services or wholesale services for pharmaceutical, veterinary and sanitary preparations and medical supplies; retail services or wholesale services for cosmetics, toiletries, dentifrices, soaps and detergents. Educational and instruction services relating to arts, crafts, sports or general knowledge; teaching; educational and instruction services; teaching in the field of cosmetics and medicines; arranging, conducting and organization of seminars; arranging and conducting of seminars, workshops [education], congresses, colloquia, distance learning courses and exhibitions for cultural purposes; providing electronic publications; providing videos from the internet, not downloadable; providing digital music from the internet, not downloadable; providing images from the internet, not downloadable; entertainment services; entertainment information; photography. Designing of machines, apparatus, instruments [including their parts] or systems composed of such machines, apparatus and instruments; design services; computer programming; creation, design and maintenance of web sites; creation, maintenance, and updating of computer software; monitoring of computer systems by remote access; testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs; quality control; rental of computers; providing computer programs on data networks; rental of web servers; cloud computing; software as a service [SaaS]; platform as a service [PaaS]; hosting computer sites [web sites]; electronic data storage. Providing information about beauty; beauty consultancy; provision of medical information; providing information relating to ophthalmology services; dietary and nutritional guidance; providing information relating to dietary and nutritional guidance; providing information relating to nursing care; nursing home services; medical equipment rental; providing information relating to the rental of medical machines and apparatus; health care.

Abrégé

The problem addressed by the present invention is that of searching for an easy-to-handle diquafosol/preservative combination for preparing a diquafosol ophthalmic solution that does not exhibit a change in formulation, is clear in color, and also has sufficient preservative efficacy.　The present invention is an aqueous ophthalmic solution containing diquafosol or a salt thereof as an active ingredient, and containing an alkyldiaminoethylglycine or a salt thereof.

Classes IPC  ?

• A61K 31/7084 - Composés ayant deux nucléosides ou nucléotides, p. ex. dinucléotide de la nicotinamide-adénine, dinucléotide de la flavine-adénine
• A61K 9/08 - Solutions
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61P 27/02 - Agents ophtalmiques
• A61P 27/04 - Larmes artificiellesSolutions d'irrigation

Abrégé

The present invention addresses the problem of searching for an easily handleable combination of diquafosol and an antiseptic agent when producing a clear diquafosol eye drop having sufficient preservation efficacy.　The present invention is an aqueous eye drop which contains diquafosol or a salt thereof as an active ingredient and contains polidronium chloride.

Classes IPC  ?

• A61K 31/7084 - Composés ayant deux nucléosides ou nucléotides, p. ex. dinucléotide de la nicotinamide-adénine, dinucléotide de la flavine-adénine
• A61K 9/08 - Solutions
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
• A61P 27/02 - Agents ophtalmiques
• A61P 27/04 - Larmes artificiellesSolutions d'irrigation

Abrégé

The present invention addresses the problem of exploring an additional combination of diquafosol and a preservative, said combination enabling the preparation of a clear diquafosol ophthalmic solution, while having sufficient preservative efficacy.　The present invention provides an aqueous ophthalmic solution which contains diquafosol or a salt thereof as an active ingredient, while also containing polyhexamethylene biguanide or a salt thereof.

Classes IPC  ?

• A61K 31/7084 - Composés ayant deux nucléosides ou nucléotides, p. ex. dinucléotide de la nicotinamide-adénine, dinucléotide de la flavine-adénine
• A61K 9/08 - Solutions
• A61K 47/16 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant de l'azote
• A61P 27/02 - Agents ophtalmiques
• A61P 27/04 - Larmes artificiellesSolutions d'irrigation

Abrégé

The present disclosure provides and an agent for treating or preventing an eye disease such as presbyopia, comprising, as an active ingredient, a lipoic acid prodrug having a specified structure.

Classes IPC  ?

• A61K 31/385 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant plusieurs atomes de soufre dans le même cycle
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions
• A61P 27/10 - Agents ophtalmiques pour le traitement des troubles d'accommodation, p. ex. myopie

Abrégé

An inserter device is provided for use with a glaucoma drainage device including a tube having a proximal end and a distal end with a lumen extending from the proximal end to the distal end. The inserter device includes an elongate member having a distal end defining a stop surface, and a stylus extending beyond the distal end of the elongate member. The stylus is sized and configured to be received within the lumen of the glaucoma drainage device with the stop surface interfacing to and limiting proximal movement of the glaucoma drainage device. The stylus has a first length that extends beyond the stop surface that is less than a second length of a portion of the lumen of the tube of the glaucoma drainage device that extends beyond the stop surface. Systems and methods are also described and claimed.

Classes IPC  ?

• A61F 9/007 - Procédés ou dispositifs pour la chirurgie de l'œil
• A61B 17/34 - TrocartsAiguilles à ponction
• A61F 9/008 - Procédés ou dispositifs pour la chirurgie de l'œil utilisant un laser
• A61M 27/00 - Appareillage pour drainage des blessures

Produits et services

Collyrium; eye drops; ophthalmic pharmaceutical preparations; ophthalmological preparations; pharmaceutical preparations for treatment of cataracts; pharmaceutical preparations for treatment of glaucoma; pharmaceutical preparations for treatment of ocular hypertension; ophthalmic ointments, creams, lotions and gels; pharmaceutical preparations for use in eye injections; pharmaceutical preparations for treatment of pinguecula; pharmaceutical preparations for treatment of chalazion; pharmaceutical preparations for treatment of uveitis; pharmaceutical preparations for improving focus-adjustment function declined by accommodative asthenopia; pharmaceutical preparations for treatment of accommodative asthenopia; eye drops for treatment of keratoconjunctival epithelial disorder; antibacterial eye drops; antiallergic eye drops; pharmaceutical preparations; reagent paper for medical purposes; oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for medical use; capsules for medicines; eyepatches for medical purposes; ear bandages for medical purposes; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; cotton sticks for medical purposes; diapers; diaper covers; dietary supplements for humans; nutritional supplements; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; dietary supplements for animals.

Abrégé

To prove an optical probe that can illuminate an entire desired region at one time, even in a narrow space. An optical probe including: a linear light guide to guide light from a light source device; a planar emitter to be connected to a tip portion of the linear light guide, to emit the light; a reflective surface provided in a part of the planar emitter, to reflect the light having entered the planar emitter; and an emitting surface provided so as to face the reflective surface, to allow the light reflected by the reflective surface to be emitted from a region of the reflective surface.

Classes IPC  ?

• A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux

Abrégé

The present invention provides: a stable pharmaceutical composition containing (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5, 11-dihydro-6H-pyrido[2, 3-b][1, 4]benzodiazepine-6-one or a salt thereof; and a method for stabilizing (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5, 11-dihydro-6H-pyrido[2, 3-b][1, 4]benzodiazepine-6-one or a salt thereof.

Classes IPC  ?

• A61K 9/06 - OnguentsExcipients pour ceux-ci
• A61K 9/08 - Solutions
• A61K 31/5513 - 1,4-Benzodiazépines, p. ex. diazépam
• A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61P 27/02 - Agents ophtalmiques

Abrégé

The present invention provides: a stable pharmaceutical composition containing (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5, 11-dihydro-6H-pyrido[2, 3-b][1, 4]benzodiazepine-6-one or a salt thereof; and a method for stabilizing (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5, 11-dihydro-6H-pyrido[2, 3-b][1, 4]benzodiazepine-6-one or a salt thereof.

Classes IPC  ?

• A61K 31/5513 - 1,4-Benzodiazépines, p. ex. diazépam
• A61K 9/06 - OnguentsExcipients pour ceux-ci
• A61K 9/08 - Solutions
• A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61P 27/02 - Agents ophtalmiques

Abrégé

The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.

Classes IPC  ?

• A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
• A61P 27/10 - Agents ophtalmiques pour le traitement des troubles d'accommodation, p. ex. myopie
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

The present disclosure relates to bispecific binding molecules against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2), including protein sequences, methods for their production, pharmaceutical compositions containing the bispecific binding molecules, and therapeutic and diagnostic uses thereof.

Classes IPC  ?

• C07K 19/00 - Peptides hybrides
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 27/04 - Larmes artificiellesSolutions d'irrigation
• C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
• C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
• C12N 15/12 - Gènes codant pour des protéines animales
• C12N 15/13 - Immunoglobulines
• C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion
• C12P 21/08 - Anticorps monoclonaux

Abrégé

The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.

Classes IPC  ?

• A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 27/10 - Agents ophtalmiques pour le traitement des troubles d'accommodation, p. ex. myopie

Abrégé

The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, 4-phenylbutyric acid or an ester thereof, or a pharmaceutically acceptable salt thereof.

Classes IPC  ?

• A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
• A61P 27/10 - Agents ophtalmiques pour le traitement des troubles d'accommodation, p. ex. myopie
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Produits et services

Educational services. Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; hosting websites. Medical services; providing medical information; medical counselling services; provision of pharmaceutical information.

Abrégé

Provided is an ophthalmic composition comprising diquafosol or a salt thereof, a vinyl-based polymer and a cellulose-based polymer. Also provided is an agent for prevention or treatment of dry eyes, comprising diquafosol or a salt thereof, a vinyl-based polymer and a cellulose-based polymer. These solution-type aqueous eye drop for treatment of dry eye each comprises diquafosol sodium with a concentration of 3% (w/v), hydroxyethyl cellulose and polyvinylpyrrolidone having a K value of 30, and is characterized in that a single dose of 1 to 2 drops is administered by eye drop three times per day.

Classes IPC  ?

• A61K 31/7042 - Composés ayant des radicaux saccharide et des hétérocycles
• A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
• A61K 47/38 - CelluloseSes dérivés
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.

Classes IPC  ?

• A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
• A61P 27/06 - Agents antiglaucomateux ou myotiques
• A61P 27/02 - Agents ophtalmiques
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

The purpose of the present invention is to identify a drug formulation for the treatment or prevention of glaucoma or ocular hypertension, wherein the drug formulation exhibits an effect in patients with drug-refractory glaucoma or ocular hypertension.　Sepetaprost is expected to exhibit an excellent intraocular pressure-lowering action in patients with otherwise drug-refractory glaucoma or ocular hypertension. The drug formulation according to the present invention containing sepetaprost as an active ingredient is therefore useful as a drug formulation that can treat or prevent glaucoma or ocular hypertension in patients with otherwise drug-refractory glaucoma or ocular hypertension.

Classes IPC  ?

• A61K 31/558 - Eicosanoïdes, p. ex. leucotriènes ayant des hétérocycles contenant l'oxygène comme seul hétéro-atome du cycle, p. ex. thromboxanes
• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61P 27/06 - Agents antiglaucomateux ou myotiques

Abrégé

The present invention relates to a pharmaceutical composition for treating myopia, preventing myopia and/or suppressing myopia progression, comprising (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof as an active ingredient, wherein the pharmaceutical composition is substantially free of (-)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof.

Classes IPC  ?

• A61K 9/06 - OnguentsExcipients pour ceux-ci
• A61K 9/08 - Solutions
• A61K 31/5513 - 1,4-Benzodiazépines, p. ex. diazépam
• A61P 27/02 - Agents ophtalmiques
• A61P 27/06 - Agents antiglaucomateux ou myotiques

Abrégé

A drive unit 100 for liquid ejection allows a user to eject a fixed amount of liquid easily and economically without complicating manufacturing tasks and liquid replenishment tasks, and is for actuating a pump bottle 10 having a discharge port 13, a storage part 11, and a support base 12, the pump bottle being configured such that when the storage part 11 moves, relative to the support base 12, from a normal state position to an operation position, liquid stored in the storage part 11 is ejected through the discharge port 13. This drive unit for liquid ejection comprises: a unit body 20 that allows installation of the pump bottle 10 with the discharge port 13 exposed to the outside; a pusher 35 which is provided to the unit body 20 such that the pusher can face the pump bottle 10 installed to the unit body 20 and can move along the movement direction of the storage part 11; and a main drive member 31, a driven member 32, and a biasing spring 33 which are for moving, relative to the unit body 20, the pusher 35 between the normal state position and the operation position, such movement driven by an electric motor 40.

Classes IPC  ?

• A61M 11/00 - Pulvérisateurs ou vaporisateurs spécialement destinés à des usages médicaux

Abrégé

The present invention relates to a pharmaceutical composition for treating myopia, preventing myopia and/or suppressing myopia progression, comprising (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof as an active ingredient, wherein the pharmaceutical composition is substantially free of (-)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof.

Classes IPC  ?

• A61K 31/5513 - 1,4-Benzodiazépines, p. ex. diazépam
• A61K 9/06 - OnguentsExcipients pour ceux-ci
• A61K 9/08 - Solutions
• A61P 27/02 - Agents ophtalmiques
• A61P 27/06 - Agents antiglaucomateux ou myotiques

Abrégé

The present invention provides an improvement in the strength of the scleral by collagen fiber crosslinking via crosslinking treatment of the sclera at the equatorial region of the eye and/or at the posterior pole such as the fundus of the eye. Also provided is the prevention and/or treatment of eye disease by the same. Provided are: a photosensitizer used in a crosslinking treatment for the sclera at the equatorial region of the eye and/or at the posterior pole of the eye; a kit containing the same; and a method for emitting light for the crosslinking treatment.

Classes IPC  ?

• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61F 9/007 - Procédés ou dispositifs pour la chirurgie de l'œil
• A61K 31/525 - Iso-alloxazines, p. ex. riboflavines, vitamine B2
• A61K 31/661 - Acides du phosphore ou leurs esters n'ayant pas de liaison P-C, p. ex. fosfosal, dichlorvos, malathion
• A61K 31/7084 - Composés ayant deux nucléosides ou nucléotides, p. ex. dinucléotide de la nicotinamide-adénine, dinucléotide de la flavine-adénine
• A61K 41/17 - Inactivation ou décontamination d'une préparation médicinale avant son administration à un animal ou une personne par lumière ultraviolette [UV] ou infrarouge [IR], rayons X ou rayons gamma
• A61P 27/10 - Agents ophtalmiques pour le traitement des troubles d'accommodation, p. ex. myopie

Abrégé

The present invention provides a novel VEGF-binding peptide or a compound including a novel VEGF-binding peptide structure. For example, the present invention provides a compound represented by the following formula (I) (where peptide A is represented by the following formula (A), and each of the groups is as defined in the description) or a pharmaceutically acceptable salt thereof.

Classes IPC  ?

• C07K 7/50 - Peptides cycliques contenant au moins une liaison peptidique anormale
• A61K 38/12 - Peptides cycliques
• A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
• A61P 7/10 - Agents antiœdémateuxDiurétiques
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
• A61P 27/02 - Agents ophtalmiques
• A61P 27/06 - Agents antiglaucomateux ou myotiques
• A61P 27/10 - Agents ophtalmiques pour le traitement des troubles d'accommodation, p. ex. myopie
• A61P 35/00 - Agents anticancéreux
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

A promoting agent for the secretion of a lipid, which contains diquafosol or a salt thereof as an active ingredient, in which the type of the secretion of the lipid is of a holocrine type. An ophthalmic composition containing diquafosol or a salt thereof as an active ingredient, which is intended to be used for the promotion of the secretion of a lipid, in which the type of the secretion of the lipid is of a holocrine type. An ophthalmic composition containing diquafosol or a salt thereof, which is intended to be used in an in vivo treatment method for promoting the holocrine-type secretion of a lipid from a meibomian gland cell. An ophthalmic composition containing diquafosol or a salt thereof, which is intended to be used in an in vivo treatment method for promoting the secretion of a lipid from a meibomian gland cell, in which the lipid is at least one component selected from the group consisting of a wax ester, a triglyceride, an omega-hydroxy lipid, cholesterol, a cholesterol ester, total cholesterol, a phospholipid, a fatty acid and a fatty alcohol.

Classes IPC  ?

• A61K 31/7084 - Composés ayant deux nucléosides ou nucléotides, p. ex. dinucléotide de la nicotinamide-adénine, dinucléotide de la flavine-adénine
• A61P 27/02 - Agents ophtalmiques

Abrégé

The present disclosure provides an agent for treating or preventing ophthalmopathy such as presbyopia, the agent containing as an active ingredient a sulfur-containing compound having a prescribed structure.

Classes IPC  ?

• A61K 31/095 - Composés du soufre, du sélénium ou du tellure, p. ex. thiols
• A61K 31/385 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant plusieurs atomes de soufre dans le même cycle
• A61P 27/02 - Agents ophtalmiques
• A61P 27/10 - Agents ophtalmiques pour le traitement des troubles d'accommodation, p. ex. myopie
• C07C 323/12 - Thiols, sulfures, hydropolysulfures ou polysulfures substitués par des halogènes, des atomes d'oxygène ou d'azote ou par des atomes de soufre ne faisant pas partie de groupes thio contenant des groupes thio et des atomes d'oxygène, liés par des liaisons simples, liés au même squelette carboné ayant les atomes de soufre des groupes thio liés à des atomes de carbone acycliques du squelette carboné le squelette carboné étant acyclique et saturé
• C07D 339/04 - Cycles à cinq chaînons comportant les hétéro-atomes en positions 1, 2, p. ex. acide lipoïque

Produits et services

Educational services. Scientific and technological services; offering scientific information on diseases and on the treatment thereof; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; hosting of websites. Medical services; healthcare services; providing of medical information; medical counselling services; provision of pharmaceutical information.

Abrégé

A preventive or therapeutic agent for glaucoma or ocular hypertension includes a combination of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl) aminomethyl}pyridin-2-ylamino)acetate with one or more other preventive or therapeutic drugs for glaucoma or ocular hypertension, with the proviso that tafluprost is excluded.

Classes IPC  ?

• A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
• A61K 31/225 - Acides polycarboxyliques
• A61K 31/4178 - 1,3-Diazoles non condensés et contenant d'autres hétérocycles, p. ex. pilocarpine, nitrofurantoïne
• A61K 31/498 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinoxaline, phénazine
• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• A61K 31/542 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes hétérocycliques
• A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p. ex. clozapine, dilazèpe
• A61K 31/5575 - Eicosanoïdes, p. ex. leucotriènes ayant un cycle cyclopentane, p. ex. prostaglandine E2, prostaglandine F2-alpha
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles

Abrégé

The present invention provides an aqueous composition for enhancing transferability into ocular tissue, the aqueous composition containing epinastine or a salt thereof and a quaternary ammonium compound, wherein the content ratio of the quaternary ammonium compound with respect to the epinastine or salt thereof is 0.1 part by weight or less with respect to 1 part by weight of the content of the epinastine or salt thereof.

Classes IPC  ?

• A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
• A61K 9/08 - Solutions
• A61K 47/16 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant de l'azote
• A61P 27/02 - Agents ophtalmiques

Abrégé

The present invention pertains to an ophthalmic aqueous composition containing a silver salt, wherein a polyester resin container or a polyolefin (excluding polypropylene) resin container is filled with the ophthalmic aqueous composition. The present invention also pertains to: an ophthalmic preservative containing a silver salt, wherein a polyester resin container or a polyolefin (excluding polypropylene) resin container is filled with the ophthalmic preservative; and a method for imparting storage efficacy that meets the storage efficacy test standards of the Japan Pharmacopoeia to an ophthalmic aqueous composition, wherein the method includes a step for adding a silver salt to the ophthalmic aqueous composition, and a step for filling a polyester resin container or a polyolefin (excluding polypropylene) resin container with the ophthalmic aqueous composition. The present invention provides a preservative/system that can be widely used in ophthalmic aqueous compositions irrespective of types of active ingredients and additives.

Classes IPC  ?

• A61J 1/05 - Récipients spécialement adaptés à des fins médicales ou pharmaceutiques pour recueillir, stocker ou administrer du sang, du plasma ou des liquides à usage médical
• A61K 9/08 - Solutions
• A61K 31/4704 - 2-Quinolones, p. ex. carbostyrile
• A61K 31/7084 - Composés ayant deux nucléosides ou nucléotides, p. ex. dinucléotide de la nicotinamide-adénine, dinucléotide de la flavine-adénine
• A61K 47/02 - Composés inorganiques
• A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
• A61P 27/02 - Agents ophtalmiques

Abrégé

The present invention pertains to an ophthalmic aqueous composition containing a silver salt, wherein a polyester resin container or a polyolefin (excluding polypropylene) resin container is filled with the ophthalmic aqueous composition. The present invention also pertains to: an ophthalmic preservative containing a silver salt, wherein a polyester resin container or a polyolefin (excluding polypropylene) resin container is filled with the ophthalmic preservative; and a method for imparting storage efficacy that meets the storage efficacy test standards of the Japan Pharmacopoeia to an ophthalmic aqueous composition, wherein the method includes a step for adding a silver salt to the ophthalmic aqueous composition, and a step for filling a polyester resin container or a polyolefin (excluding polypropylene) resin container with the ophthalmic aqueous composition. The present invention provides a preservative/system that can be widely used in ophthalmic aqueous compositions irrespective of types of active ingredients and additives.

Classes IPC  ?

• A61K 47/02 - Composés inorganiques
• A61J 1/05 - Récipients spécialement adaptés à des fins médicales ou pharmaceutiques pour recueillir, stocker ou administrer du sang, du plasma ou des liquides à usage médical
• A61K 9/08 - Solutions
• A61K 31/4704 - 2-Quinolones, p. ex. carbostyrile
• A61K 31/7084 - Composés ayant deux nucléosides ou nucléotides, p. ex. dinucléotide de la nicotinamide-adénine, dinucléotide de la flavine-adénine
• A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
• A61P 27/02 - Agents ophtalmiques

Abrégé

The present invention makes it possible to prepare a rebamipide-containing aqueous suspension that has similar properties to Mucosta® ophthalmic suspension UD2%, without using PVA as an additive, from an aqueous suspension that contains rebamipide or a salt thereof and at least one polymer selected from the group consisting of carmellose sodium, dextran, and polyvinylpyrrolidone.

Classes IPC  ?

• A61K 31/4704 - 2-Quinolones, p. ex. carbostyrile
• A61K 9/10 - DispersionsÉmulsions
• A61K 47/02 - Composés inorganiques
• A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
• A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
• A61K 47/38 - CelluloseSes dérivés
• A61P 27/02 - Agents ophtalmiques

Produits et services

Pharmaceutical preparations for the treatment of cataracts, glaucoma, ocular hypertension, pinguecula, chalazion, uveitis, and eye diseases and conditions; pharmaceutical preparations, namely, collyrium, eye drops, ophthalmic preparations, and ophthalmic ointments for the treatment of eye diseases and conditions; pharmaceutical preparations for use in eye injections for the treatment of eye diseases and conditions

Abrégé

A device implantable into the eye that includes an elongate duct portion defining two lumens that extend parallel to one another from a distal end to a neck spaced longitudinally from the distal end, a second portion including two tubular segments that extend or flare outwardly from the neck opposite one another with at least one additional tubular segment that extends between the two tubular segments such that the tubular segments of the second portion form a tubular loop that surrounds an interior area. The tubular segments of the second portion that form the tubular loop define a common lumen with a plurality of outlets that are in fluid communication with the two lumens of the duct portion to permit fluid to flow through the device.

Classes IPC  ?

• A61F 9/007 - Procédés ou dispositifs pour la chirurgie de l'œil
• A61F 9/00 - Procédés ou dispositifs pour le traitement des yeuxDispositifs pour mettre en place des verres de contactDispositifs pour corriger le strabismeAppareils pour guider les aveuglesDispositifs protecteurs pour les yeux, portés sur le corps ou dans la main

Abrégé

Implantable devices and systems and methods are provided for controlled delivery of a therapeutic agent to the eye, which employ a flexible reservoir for holding a supply of the therapeutic agent, and a flexible tube that extends from the reservoir. The tube has an inlet end in fluid communication with the interior space of the reservoir, an outlet end spaced from the reservoir, and a lumen that extends from the inlet end to the outlet end. The lumen of the tube is configured to deliver therapeutic agent from the reservoir through the tube.

Classes IPC  ?

• A61F 9/00 - Procédés ou dispositifs pour le traitement des yeuxDispositifs pour mettre en place des verres de contactDispositifs pour corriger le strabismeAppareils pour guider les aveuglesDispositifs protecteurs pour les yeux, portés sur le corps ou dans la main
• A61M 39/04 - Voies d'accès avec des éléments perforables auto-obturants

Abrégé

−11 mol/L or less.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/00 - Agents anticancéreux
• C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance

Abrégé

The present invention provides a drug composition for treating nearsightedness, preventing nearsightedness, and/or minimizing progression of nearsightedness, including, as an active ingredient, 4-{(3S, 5ar, 6R, 7R, 8aS)-6-[(1E, 3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-butene-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butanoic acid, an ester thereof or a salt thereof.

Classes IPC  ?

• A61K 31/558 - Eicosanoïdes, p. ex. leucotriènes ayant des hétérocycles contenant l'oxygène comme seul hétéro-atome du cycle, p. ex. thromboxanes
• A61K 9/06 - OnguentsExcipients pour ceux-ci
• A61K 9/08 - Solutions
• A61K 9/10 - DispersionsÉmulsions
• A61P 27/06 - Agents antiglaucomateux ou myotiques
• A61P 27/10 - Agents ophtalmiques pour le traitement des troubles d'accommodation, p. ex. myopie

Abrégé

The present invention provides a pharmaceutical composition for treating myopia, preventing myopia, and/or suppressing progression of myopia, the pharmaceutical composition containing omidenepag or an ester thereof, or a salt of these, as an active ingredient.

Classes IPC  ?

• A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
• A61K 9/06 - OnguentsExcipients pour ceux-ci
• A61K 9/08 - Solutions
• A61K 9/10 - DispersionsÉmulsions
• A61P 27/06 - Agents antiglaucomateux ou myotiques
• A61P 27/10 - Agents ophtalmiques pour le traitement des troubles d'accommodation, p. ex. myopie

Abrégé

The purpose of the present invention is to provide an aqueous suspension composition comprising poorly water-soluble sirolimus or a salt thereof for ophthalmology, in particular, used for topical administration, such as a less invasive eye drop. The present invention is an ophthalmic aqueous suspension composition comprising sirolimus or a salt thereof and a surfactant, wherein the aqueous suspension composition has a pH of 4 to 6.

Classes IPC  ?

• A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
• A61P 27/02 - Agents ophtalmiques

Abrégé

The purpose of the present invention is to provide an aqueous suspension composition that contains poorly soluble sirolimus and that is for use in ophthalmology, especially in topical administration of less-invasive eye drops or the like.　This aqueous suspension composition is for use in ophthalmology, contains a surfactant and sirolimus or a salt thereof, and has a pH of 4-6.

Classes IPC  ?

• A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
• A61K 9/10 - DispersionsÉmulsions
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 47/38 - CelluloseSes dérivés
• A61P 27/02 - Agents ophtalmiques

Abrégé

The present invention relates to the use of valproic acid for reducing post-operative scarring following a glaucoma surgery. In one embodiment, the glaucoma surgery is glaucoma filtering surgery, which comprises creating a subconjunctival bleb. In another embodiment, the glaucoma surgery is minimally invasive glaucoma surgery (MIGS), which comprises implanting a glaucoma tube shunt under a subconjunctival space.

Classes IPC  ?

• A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque

Abrégé

According to some embodiments, a syringe may include a barrel; a delivery conduit; a plunger seal disposed within the barrel; and a plunger rod assembly affixed to an end of the barrel, the plunger rod assembly including a first plunger rod component comprising a first linear gear, a second plunger rod component disposed at least partially in the barrel and engaged with the plunger seal, wherein the second plunger rod component comprises a second linear gear, a first rotational gear having a plurality of gear teeth for engaging the first linear gear, and a second rotational gear having a second plurality of gear teeth for engaging the second linear gear, wherein the first rotational gear is coupled to the second rotational gear such that translation of the first plunger rod component causes translation of the second plunger rod component.

Classes IPC  ?

• A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras
• A61M 35/00 - Dispositifs pour appliquer des agents, p. ex. des remèdes, sur le corps humain
• A61M 5/315 - PistonsTiges de pistonGuidage, blocage, ou limitation des mouvements de la tigeAccessoires disposés sur la tige pour faciliter le dosage
• A61F 9/00 - Procédés ou dispositifs pour le traitement des yeuxDispositifs pour mettre en place des verres de contactDispositifs pour corriger le strabismeAppareils pour guider les aveuglesDispositifs protecteurs pour les yeux, portés sur le corps ou dans la main
• A61M 5/31 - Seringues Parties constitutives
• A61M 5/34 - Structures pour le raccordement de l'aiguille
• A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
• A61M 39/10 - Raccords ou accouplements pour tubes

Abrégé

The present invention relates to the use of valproic acid for reducing post-operative scarring following a glaucoma surgery. In one embodiment, the glaucoma surgery is glaucoma filtering surgery, which comprises creating a subconjunctival bleb. In another embodiment, the glaucoma surgery is minimally invasive glaucoma surgery (MIGS), which comprises implanting a glaucoma tube shunt under a subconjunctival space.

Classes IPC  ?

• A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
• A61P 41/00 - Médicaments utilisés en chirurgie, p. ex. adjuvants chirurgicaux pour la prévention des adhérences ou pour le remplacement de l'humeur vitrée

Produits et services

Educational services.

Produits et services

(1) Educational services, namely, conducting virtual and in-person educational events consisting of classes, webinars, workshops and training in the field of medicine.